VANCOUVER and HILDEN, Germany, October 17, 2016 /PRNewswire/
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAseq® cfDNA All-in-One Kit, combining cell-free DNA extraction and library preparation in the first dedicated solution for liquid biopsy analysis on any next-generation sequencing (NGS) platform. The new kit integrates with QIAGEN's recently launched PAXgene® Blood ccfDNA Tube for collection and stabilization of blood samples, as well as with the market's first bioinformatics workflow for cfDNA also introduced today by QIAGEN, creating a streamlined testing solution that allows faster, more convenient and reliable analysis of cell-free DNA from sample collection to interpreted result.
Furthermore, QIAGEN unveiled an enhanced bioinformatics workflow for hereditary and rare diseases, offering unique capabilities for research using liquid biopsies in non-invasive prenatal testing (NIPT) as well as cancer biomarker discovery. QIAGEN is rolling out the solutions at the American Society of Human Genetics ASHG 2016 Annual Meeting in Vancouver.
Click here for the full press release
Public Relations: Dr. Thomas Theuringer Senior Director Public Relations +49-2103-29-11826
Email: email@example.com http://www.twitter.com/qiagen https://www.facebook.com/QIAGEN pr.qiagen.com
Investor Relations: John Gilardi Vice President Corporate Communications and Investor Relations +49-2103-29-11711 Email: firstname.lastname@example.org ir.qiagen.com
SOURCE QIAGEN N.V.
Subscribe to our Free Newsletters!
This is a branch of telemedicine that delivers eye care via a digital medical equipment and ...
Inborn errors of metabolism are genetic disorders that hamper the body''s metabolism resulting in ...
Neuroblastoma is a very rare type of childhood cancer that develops in immature nerve cells ...View All